Creatine and Menopause: Muscle, Strength, Bone and Brain Evidence

Creatine and menopause is one of the most interesting newer creatine topics because midlife women face changes in muscle, strength, bone and body composition at the same time that the historical creatine literature has been heavily male dominated.

The strongest current claim is not that creatine “balances hormones.” It is that creatine may modestly enhance resistance-training effects on lean mass and strength in postmenopausal women.

2026 postmenopausal meta-analysis: lean mass, strength and bone in numbers

Outcome	Pooled result	Interpretation
Lean mass	+0.37 kg versus control	A small pooled benefit; strongest in protocols combining at least 5 g/day with resistance training.
Leg-press 1RM	+7.5 kg versus control	Supports a lower-body strength benefit in the included trials.
Bone mineral density	No significant pooled improvement	Creatine should not be presented as an osteoporosis treatment or proven fracture-prevention strategy.

The review included seven randomized trials and 608 randomized participants, with interventions lasting 12 to 104 weeks. These numbers are more useful than a generic “creatine may help menopause” claim because they show both the magnitude of benefit and its limits.

What about perimenopause?

Direct perimenopause-specific supplementation evidence remains limited. The 2025 women's-health review highlights perimenopause as a research priority. Until dedicated trials are available, claims for women in the menopausal transition should be described as extrapolation from younger active women, postmenopausal trials and general creatine physiology—not as directly proven perimenopause outcomes.

Creatine and muscle loss after menopause

Loss of estrogen is one of several factors that can influence muscle remodeling, recovery and physical function with age. Creatine supports rapid cellular energy turnover and can help repeated high-intensity muscular work. Over time, that may allow a larger or higher-quality training stimulus.

The evidence does not show that every postmenopausal woman will gain a predictable amount of muscle from creatine alone.

Creatine and strength

Strength is one of the more convincing outcomes. The 2026 menopause meta-analysis reported an improvement in leg-press strength, and the broader older-adult literature finds a modest additional strength benefit when creatine is combined with resistance training.

Creatine and bone density

Bone is a common reason women investigate creatine after menopause, but current evidence is less convincing than for strength. The 2026 meta-analysis did not establish a clear overall improvement in bone mineral density.

Creatine should therefore not be marketed as an osteoporosis treatment. Resistance and impact exercise, calcium and vitamin D adequacy, fall prevention, bone-density assessment and prescription therapy where indicated remain the evidence-based foundations.

Creatine and brain health around menopause

Brain-energy metabolism is a plausible area of interest, but menopause-specific cognitive trials remain limited. A 2026 review of cognition in older adults found mostly positive associations, yet only two studies were double-blind supplementation trials. Broader cognitive meta-analyses are mixed.

It is reasonable to describe cognition as an emerging benefit area, not a proven menopause therapy.

Does creatine help menopausal weight gain?

Creatine is not a direct fat-loss supplement. It may support resistance training and lean mass, which is valuable for long-term body composition, but fat loss still depends primarily on energy balance. Early creatine-associated scale gain is often water rather than fat.

Creatine dose after menopause

The standard adult maintenance range of 3–5 g/day remains a practical starting point. The 2026 postmenopausal meta-analysis found stronger signals in studies using at least 5 g/day with resistance training. That does not prove every woman needs more than 5 g or that increasing dose produces increasing benefit.

Do you need to load?

No. Loading is optional at any age. A daily maintenance dose eventually increases tissue stores and may be easier to tolerate.

Safety in postmenopausal women

A broader female safety meta-analysis did not find increased serious adverse events, GI events or renal/hepatic complications across the available female trials. However, postmenopausal adults are more likely than younger athletes to have CKD, hypertension or multiple medications, so individual medical context matters.

Creatine and kidney tests

Creatine can raise serum creatinine and make creatinine-based eGFR look lower without equivalent change in directly measured filtration. If kidney function is being monitored, tell the clinician about supplementation so labs can be interpreted appropriately.

Perimenopause vs postmenopause

Most of the strongest life-stage-specific data currently come from postmenopausal women, not every point in perimenopause. The broader adult creatine evidence still applies to muscle energetics, but menopause-specific claims should not be generalized beyond the populations studied.

What the newest menopause and bone evidence says

Postmenopausal women are one of the most interesting populations for creatine because the practical goal is not simply bigger muscles—it is maintaining strength, lean tissue and independence as hormonal changes accelerate musculoskeletal decline. A 2026 meta-analysis found small improvements in lean mass and lower-body strength in postmenopausal women, particularly when creatine was paired with resistance training; pooled bone-mineral-density effects were not clearly improved.

That bone finding matters. A separate two-year randomized trial in 237 postmenopausal women used creatine alongside resistance training and walking. Creatine did not significantly improve femoral-neck, total-hip or lumbar-spine BMD compared with placebo, although some proximal-femur geometry measurements favored creatine. Those geometry findings are interesting but should not be marketed as proven fracture prevention.

The practical interpretation is strong for muscle and more cautious for bone: resistance training, adequate protein and clinically appropriate bone-health care remain foundational. Creatine can be considered an adjunct for training adaptations rather than a replacement for osteoporosis evaluation or treatment.

See the women's guide, older-adult guide and 89-paper Data Center.

A separate 2026 trial tested creatine HCl—not monohydrate

The CONCRET-MENOPA trial adds a different menopause research angle, but it must not be blended into the monohydrate evidence. Thirty-six perimenopausal or menopausal women were randomized across four groups for eight weeks. The 1,500 mg/day creatine-HCl arm showed greater changes than placebo in reaction time and frontal brain creatine, while the study also explored a creatine-HCl/ethyl-ester combination.

This is scientifically interesting but does not show that creatine HCl is superior to monohydrate: there was no monohydrate comparator, the sample was small and divided among four arms, and the study was partially funded by Vireo Systems, which supplied the interventions. The senior author also disclosed multiple creatine-related commercial interests. For muscle and strength after menopause, the larger monohydrate meta-analysis remains the more directly applicable evidence base. See the trial record.

Perimenopausal brain-creatine study: mechanism, not treatment evidence

A 2026 exploratory study used magnetic resonance spectroscopy in 12 perimenopausal women and reported lower mean brain creatine than younger reference values, with several regional associations between brain creatine, concentration complaints and estradiol. No creatine supplement was administered.

This belongs in the menopause evidence map because it supports a biologically plausible brain-energy question, but it cannot show that low brain creatine causes symptoms or that supplementation corrects them. Read the cross-sectional study.

A separate 2026 women’s musculoskeletal meta-analysis pooled several supplement classes and found no robust overall muscle-mass or bone benefit; only three included trials used creatine. That makes it supportive context, not a replacement for the creatine-specific postmenopausal meta-analysis already covered above. See the broader women’s meta-analysis.

Bottom line

For postmenopausal women doing resistance training, creatine monohydrate has a reasonable evidence-based role as an adjunct for strength and possibly lean mass. Bone-density improvement is not established, and cognitive benefits remain under investigation. The formula is simple: progressive resistance training first, creatine as a potential enhancer rather than a replacement.

Key research

• 2026 postmenopausal meta-analysis
• Women's health review
• Female safety meta-analysis